A new analysis of the drug orforglipron indicates similar weight loss outcomes for women regardless of their menopausal status.
Key facts
- •The study analyzed orforglipron, an oral nonpeptide GLP-1 receptor agonist manufactured by Eli Lilly and Company.
- •Data was drawn from the ATTAIN-1 study, which focused on people without diabetes, and the ATTAIN-2 study, which focused on people with type 2 diabetes.
- •Participants had a BMI of at least 30 kg/m² or a BMI of at least 27 kg/m² with a weight-related medical condition.
- •The findings will be presented at the European Association for the Study of Diabetes annual meeting, held from Sept. 28 to Oct. 2 in Milan.
- •Orforglipron is designed as a daily oral medication for weight loss and type 2 diabetes management.
New research presented at the European Association for the Study of Diabetes meeting in Milan shows that the daily oral medication orforglipron is associated with consistent weight loss across different menopausal stages. The study, led by Dr. Hunter Thomas Hoffman of Eli Lilly and Company, analyzed data from the ATTAIN-1 and ATTAIN-2 clinical trials to evaluate the drug's effectiveness in premenopausal, perimenopausal, and postmenopausal women.
By the numbers
Study methodology and findings
The analysis included female participants with obesity or overweight status and at least one weight-related medical condition. Researchers compared the effects of orforglipron against a placebo over a 72-week period, measuring changes in body weight, waist circumference, and waist-to-height ratios. The number of women in each menopausal category ranged from 142 to 225. Results indicated that women taking orforglipron experienced significant body weight reductions of up to 14% across all three menopausal groups. Additionally, participants saw waist circumference reductions of up to 12.5 cm, or 4.9 inches.
Weight loss thresholds
The study assessed the proportion of participants who reached specific weight loss milestones. Up to 83% of women treated with orforglipron achieved a weight loss of at least 5% of their body weight, compared to 30% of those in the placebo group. Furthermore, more participants receiving the medication moved into lower waist-to-height ratio categories compared to those receiving the placebo.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Medical Xpress.
